Page last updated: 2024-10-26

famotidine and Obesity, Morbid

famotidine has been researched along with Obesity, Morbid in 1 studies

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

Research Excerpts

ExcerptRelevanceReference
"Famotidine and ranitidine were compared as agents for the prevention of acid aspiration syndrome in 32 morbidly obese patients undergoing vertical banded gastroplasty."5.07Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine. ( Canet, J; Melero, A; Vallès, J; Vidal, F; Vila, P, 1991)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vila, P1
Vallès, J1
Canet, J1
Melero, A1
Vidal, F1

Trials

1 trial available for famotidine and Obesity, Morbid

ArticleYear
Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.
    Anaesthesia, 1991, Volume: 46, Issue:11

    Topics: Adult; Famotidine; Female; Gastric Acidity Determination; Gastric Juice; Gastroplasty; Humans; Male;

1991